Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

Annals of Oncology

Volumn 14, Issue 9, 2003, Pages 1399-1405

  Body, J J ^a   Diel, I J ^b   Lichinitser, M R ^c   Kreuser, E D ^d   Dornoff, W ^e   Gorbunova, V A ^c   Budde, M ^f   Bergstrom B ^g   de Greve J S ^g   Mancini, I ^g   Van Belle, S ^g   Cavalli, F ^g   Thuerlimann, B ^g   Herrmann, R ^g   Clemens, M ^g   Eiermann, W ^g   Kaiser, G ^g   Nauen, P ^g   Obenaus, R ^g   Schindler, A E ^g   Vogt, A ^g   Hoeffken, K ^g   Ahlemann, L M ^g   Essers, U ^g   Porta, V G ^g   Ferrero, J M ^g   Pouillard, P ^g   de Gramont, A ^g   Pinon, N ^g   Reme, S ^g   Labat, J P ^g   Guillevin, L ^g   Morere, J F ^g   Krzisch, C ^g   Mechl, Z ^g   Bruland, O ^g   Andersen, O K ^g   Bremnes, R ^g   Ferreira, E P ^g   Fernandes, A ^g   Bassara, H ^g   Semiglazov, V F ^g   Hansen, J ^g   Lorenz, I ^g   Howell, A ^g   Cameron, D ^g   Tyrell, C J ^g   Powels, T J ^g   McAleer, J ^g   Barrett Lee, P J ^g   Cash, K ^g   Craig, J ^g   Decker, D A ^g   Gams, R ^g   Gottlieb, R ^g   Gucalp, R ^g   Hage Boutros, A ^g   Havlin, K ^g   Hon, J ^g   Katterhagen, J Gale ^g   Lewis, M ^g   Panella, T ^g   Plezia, P ^g   Rivkin, S ^g   Sandbach, J ^g   Wade, J ^g   Woolley, P ^g   Conkling, P ^g   Ervin, T J ^g   Martinez Rio, M ^g   Tripathy, D ^g   Meshad, M ^g   Jordaan, J P ^g   Werner, I D ^g   Falkson, G ^g   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Cancer Research Center   (Russian Federation)

^d Hospital Barmherzigen Brueder   (Germany)

^e Klinik Mutterhaus der Borromaeerinnen   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g HOFFMANN LA ROCHE INC   (United States)

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Ibandronate; Pain; Radiotherapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GALLIUM NITRATE; IBANDRONIC ACID; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYDRONEPHROSIS; LEUKOPENIA; LUNG EDEMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 17144447171     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg367     Document Type: Article

References (22)

1. Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone 1992; 13 (Suppl 1): S57-S62.
2. Theriault RL, Hortobagyi GN. Bone metastasis in breast cancer. Anticancer Drugs 1992; 3: 455-462.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80 (Suppl 8): 1588-1594.
4. Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997; 75: 408-412.
5. Body JJ, Bartl R, Burckhardt P et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998; 16: 3890-3899.
6. Fleisch H. Bisphosphonates in Bone Disease, 4th edition. San Diego, CA: Academic Press 2000.
7. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
8. Diel IJ, Solomayer E-F, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363.
9. Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998; 339: 398-400.
10. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
11. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-2044.
12. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854.
13. Ralston SH, Thiebaud D, Herrmann Z et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75: 295-300.
14. Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378-1391.
15. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomised, placebo-controlled trials. Cancer 2000; 88: 1082-1090.
16. Scott M, Möcks J, Givens S et al. Morbidity measures in the presence of recurrent composite endpoints. Pharm Stat 2003; 2: 39-49.
17. McCloskey EV, Spector TD, Eyres KS et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 1993; 3: 138-147.
18. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika 1954; 41: 133-145.
19. Terpstra TJ. The asymptotic normality and consistency of Kendalls s test against trend, when ties are present in one ranking. Indag Math 1952; 14: 327-333.
20. Diel IJ, Lichinitser MR, Body JJ et al. Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate. Eur J cancer 1999; 35 (Suppl 4): S83 (Abstr 269).
21. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001; 28 (Suppl 11): 49-53.
22. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.